Cited 0 times in
Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.